Startup Scout 19 Oct 2022 Neobe Therapeutics breaks down tumor defenses with bacteria Many cancer patients cannot benefit from cancer immunotherapy because their tumors are protected from the immune system. Neobe Therapeutics’ bacterial therapy is designed to strip the tumors of their protective barriers. The immune system is very good at fighting tumors, and cancer immunotherapies are often able to supercharge our natural defenses to great effect. However, […] October 19, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2022 Nucleome Therapeutics raises £37.5M to deliver precision medicines U.K. biotech company Nucleome Therapeutics Limited has closed an oversubscribed £37.5 million ($42.4 million) series A financing round. The funds will be used to advance the company’s autoimmune disease programs, fuel expansion of its dark genome atlas and further develop its pioneering platform. The financing was led by new investor M Ventures, the strategic, corporate […] October 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Oct 2022 Empyrean Neuroscience launches with $22M to target CNS disorders Empyrean Neuroscience, Inc. has launched with $22 million in series A financing and a genetic engineering platform to advance a pipeline of neuroactive compounds targeting disorders of the central nervous system (CNS). The company, based in New York City and Cambridge, U.K., is founded on a proprietary platform designed to genetically engineer small molecule therapeutics […] October 18, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Oct 2022 Emergex develops vaccine for smallpox and monkeypox Emergex Vaccines Holding Limited has formulated and confirmed the synthesis and assembly of a CD8+ T cell adaptive vaccine for smallpox and monkeypox, made up predominantly of early “eclipse phase” antigens. The monkeypox virus is part of the same family of double-stranded DNA viruses (Poxviridae) as variola virus, the virus that causes smallpox; they share […] October 18, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Oct 2022 Progress of COPD drug boosted by debt financing of up to $150M Verona Pharma plc has today (October 17) announced that it has entered into a debt financing facility providing access of up to $150 million from Oxford Finance LLC. The non-dilutive capital provides further financial flexibility and support for commercialization activities for ensifentrine, the company’s product candidate, which recently reported positive phase 3 data in the […] October 18, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
In Depth 17 Oct 2022 UK grants that can give biotech startups a vital jump-start Grants are a vital lifeline that help biotech startups get off the ground, especially for underrepresented entrepreneurs. The Women in Synthetic Biology (WiSB) network recently gave detailed advice for helping U.K. biotech founders access this funding. Women are a big source of talent in the biotech space, both in academic life sciences and in founding […] October 17, 2022 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2022 More positive news announced for Verona’s COPD treatment Clinical-stage biopharmaceutical company, Verona, has announced more positive news from its phase 3 ENHANCE-2 clinical trial of ensifentrine that treats chronic obstructive pulmonary disease (COPD). The company focuses on respiratory diseases, and made the announcement today (October 14) about the positive analyses demonstrating how ensifentrine reduced exacerbation rates across subgroups in the trial. Ensifentrine is […] October 17, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 14 Oct 2022Beyond Biotech podcast 18: BiotechX, Cultivated Biosciences, EPFL, Faron Pharmaceuticals This week, we have four interviews. Our guests are: Juho Jalkanen, COO of Faron Pharmaceuticals; Ardemis Boghossian and Melania Reggente from the EPFL School of Basic Sciences in Switzerland; Tomas Turner, CEO and co-founder of Cultivated Biosciences; and Joanna Magaji, conference manager for the BiotechX event. BiotechX event taking place in Basel in November BiotechX, […] October 14, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 13 Oct 2022 CMT Research Foundation funding boosts Samsara Therapeutics Charcot-Marie-Tooth treatment The CMT Research Foundation (CMTRF), a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease, has invested in Samsara Therapeutics Inc. Samsara Therapeutics is a biotech company focusing on discovering and developing therapeutics to restore autophagy – the process by which cells recycle damaged or dysfunctional components. Samsara is developing several novel, […] October 13, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2022 Amphista Therapeutics and Domainex Ltd partner for integrated drug services Amphista Therapeutics Ltd., has selected Domainex Ltd as one of its trusted partners to provide integrated drug discovery services to support its research programs. The partnership will also advance its portfolio of drug discovery projects targeting protein degradation (TPD). Targeted protein degradation (TPD) is an emerging therapeutic modality with the potential to deal with disease-causing […] October 12, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2022 Novavax COVID-19 vaccine data supports homologous and heterologous boosting Data in from adults and adolescents aged 12-17 collected in a phase 3 trial of a prototype Novavax COVID-19 vaccine showed it had achieved its pre-specified immunologic endpoint. Study 307 met its primary endpoint, showing three lots of the vaccine tested as a heterologous booster induced consistent immune responses in previously vaccinated adults aged 18-49. […] October 12, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2022 SiSaf takes steps with FDA for RNA therapeutic to treat rare genetic skeletal disorders SiSaf Ltd, an RNA delivery and therapeutics company, is initiating the U.S. FDA Regulatory process to obtain orphan drug designation for SIS-101-ADO. SIS-101-ADO is a siRNA therapeutic for patients with autosomal dominant osteopetrosis type 2 (ADO2), a rare genetic skeletal disorder. The request for orphan drug designation and advancement through the regulatory process that SIS-101-ADO […] October 12, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email